Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366004 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4369810 | 0.85 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL4369863 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL4377440 | 0.75 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL21704405 | 0.74 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL4369513 | 0.73 | ADORA2A (0.43) | ADORA2AADORA1LMNA | |
| SCHEMBL4365730 | 0.70 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL13732188 | 0.70 | STAT6 (0.52) | ADORA2AADORA1LMNA | |
| SCHEMBL6868134 | 0.69 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL6865916 | 0.68 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| EP-1363639-B1 | PYRROLO 2,3-d PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7098333-B2 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-06-15 | — | — | US | disclosed |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | CHRNA6, CNR1, ADORA2A | ADORA2A 3/4885ADORA1 11/4885ADORA3 7/4885 |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | CNR1, CNR2, CHRNA6 | ADORA2A 7/4885ADORA1 18/4885ADORA3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.